Testing effectiveness (Phase 2)Study completedNCT00493649What this trial is testingAdj TC + Herceptin Early Stage Breast CancerWho this might be right forBreast Cancer US Oncology Research 493
Large-scale testing (Phase 3)Study completedNCT00878709What this trial is testingStudy Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerWho this might be right forBreast Cancer Puma Biotechnology, Inc. 2,840
Testing effectiveness (Phase 2)Active Not RecruitingNCT02326974What this trial is testingT-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAWho this might be right forHER-2 Positive Breast CancerBreast CancerStage II Breast Cancer+1 more Dana-Farber Cancer Institute 164
Testing effectiveness (Phase 2)Study completedNCT01593020What this trial is testingNeoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2Who this might be right forBreast Cancer M.D. Anderson Cancer Center 54
Testing effectiveness (Phase 2)UnknownNCT04499118What this trial is testingAT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast CancerWho this might be right forHER2-negative Breast Cancer Sichuan Provincial People's Hospital 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07305246What this trial is testingClinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast CancerWho this might be right forBreast Cancer First Hospital of China Medical University 120
Large-scale testing (Phase 3)Study completedNCT03493854What this trial is testingEvaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerWho this might be right forEarly Breast Cancer Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Looking for participantsNCT04481932What this trial is testingTrastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast CancerWho this might be right forHER2-positive Breast Cancer Peking University 104
Testing effectiveness (Phase 2)Ended earlyNCT01194869What this trial is testingPreoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast CancerWho this might be right forBreast Cancer Emory University 25
Not applicableEnded earlyNCT03137693What this trial is testingPreoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast CancerWho this might be right forBreast CancerBreast Cancer FemaleBreast Adenocarcinoma H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT02789332What this trial is testingAssessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination DeficiencyWho this might be right forBreast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more GBG Forschungs GmbH 107
Testing effectiveness (Phase 2)UnknownNCT02993198What this trial is testingA Prospective Study of Breast Cancer Patients With Abnormal Strain ImagingWho this might be right forHER2 Positive Breast CancerCardiovascular Abnormalities Northwestern University 134
Testing effectiveness (Phase 2)Ended earlyNCT01891357What this trial is testingPhase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast CancerWho this might be right forCarcinoma, Ductal, Breast Women's Cancer Study Group GmbH 64
Testing effectiveness (Phase 2)Looking for participantsNCT07102381What this trial is testingNeoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerWho this might be right forHER2-positive Breast CancerBreast Cancer Jazz Pharmaceuticals 125
Large-scale testing (Phase 3)Study completedNCT03726879What this trial is testingEvaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 454
Large-scale testing (Phase 3)Active Not RecruitingNCT03725059What this trial is testingStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Who this might be right forBreast Cancer Merck Sharp & Dohme LLC 1,240
Large-scale testing (Phase 3)Looking for participantsNCT06492616What this trial is testingElacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceWho this might be right forBreast Cancer Stemline Therapeutics, Inc. 4,220
Large-scale testing (Phase 3)Looking for participantsNCT03201861What this trial is testingAddition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk WomenWho this might be right forTubular Breast CancerMucinous Breast CancerInvasive Duct Carcinoma of Breast RenJi Hospital 762
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07795424What this trial is testingCulmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerWho this might be right forBreast CancerHR Positive, HER2 Positive Breast Cancer Shengjing Hospital 33
Testing effectiveness (Phase 2)Looking for participantsNCT07616453What this trial is testingEfficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerWho this might be right forHR+/HER2- Early Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 45